TGTX Stock Analysis: Buy, Sell, or Hold?
TGTX - TG Therapeutics, Inc.
$55.01
-2.11 (-3.69%)
▼
5d:
-0.83%
30d:
+18.0%
90d:
+63.09%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 03, 2026
19d
Smart Money Accumulation
None View Scanner →
Strength: 4.0/10
Get Alerted When TGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
7 traders called TGTX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TGTX trades at premium valuation expecting 5.3% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: TGTX trades at premium valuation expecting 5.3% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$92.03
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$57.14
3.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TGTX is currently trading at $55.01, which is considered slightly high relative to its 30-day fair value range of $46.42 to $57.09. From a valuation perspective, the stock is trading at a premium (Forward PE: 18.3) compared to its historical average (15.7). At these levels, the market is pricing in 5.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $51.15, while resistance sits at $59.30. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $51.15, while resistance sits at $59.30. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$46.42 -
$57.09
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
53.3%
Protect Your Profits
Holding TGTX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BEARISH: Trading above Wall St target ($52.14)
- NEUTRAL: PE elevated vs history but 5.3% growth expectation is conservative given 300% recent growth
Trading Range Analysis
30-Day Trading Range
$46.42 -
$57.09
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$51.15
Resistance Level
$59.30
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.27
Wall Street Target
$52.14
(-5.2%)
Revenue Growth (YoY)
69.6%
Earnings Growth (YoY)
300.0%
Profit Margin
66.0%
Valuation Premium vs History
+5.3% premium
PE vs Historical
18.3 vs 15.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.3%
(market-implied from PE analysis)
1-Year Target
$57.93
(+5%)
2-Year Target
$61.00
(+11%)
3-Year Target
$64.23
(+17%)
3-Yr Target (if PE normalizes)
(PE: 18→16)
PE COMPRESSION
$55.18
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 97.4%)
$221.27
(+302%)
Base:
(SPY PE: 18.3, Growth: 97.4%)
$185.66
(+238%)
Bear:
(PE: 15.5, Growth: 97.4%)
$157.81
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 19.97 | Current EPS (TTM): $2.86
Bull Case
$66.13
(+20%)
Analyst growth 5.3%, PE expands to 22.0
Base Case
$60.12
(+9%)
Market implied 5.3%, PE stable at 20.0
Bear Case
$38.84
(-29%)
Severe decline -20.0%, PE contracts to 17.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 9:23 AM ET
Data refreshes hourly during market hours. Next update: 10:23 AM
Data refreshes hourly during market hours. Next update: 10:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$99 | 44 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
Advanced TGTX Option Strategies
Professional options setups generated by AI based on today's TGTX price and gamma walls.
